Filing Flows › Precision Biosciences (DTIL) › Q1 FY26
Precision Biosciences (DTIL) Q1 FY26 earnings results (first quarter fiscal 2026)
10-Q filed Aug 7, 2025
Precision Biosciences (DTIL) reported revenue of $18K for the first quarter fiscal 2026 (Q1 FY26), -100% from a year earlier and -38% from the quarter before.
Precision Biosciences, Q1 FY26: revenue $18K (-100% year over year), net loss $23.5M, operating cash flow −$20.3M. The chart follows the revenue to costs, profit and cash.
| Q1 FY26 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $18K | -38% | -100% |
| Operating profit | −$21.9M | — | — |
| Net earnings | −$23.5M | — | — |
| Operating cash flow | −$20.3M | — | — |
What changed
Revenue was $18K in Q1 FY26, down 100% year over year and down 38% from the previous quarter.
Operating costs exceeded revenue by $21.9M, an operating margin of -121538.9%. Total costs fell 15% while revenue fell 100%. The quarter ended with a net loss of $23.5M, wider than the previous quarter's $20.6M loss.
Operating cash flow was −$20.3M. Non-cash charges added back $378K of depreciation and amortization and $2.9M of share-based compensation. Capital expenditures of $2K exceeded it, leaving free cash flow of −$20.3M.
Questions
What was Precision Biosciences' revenue in the first quarter fiscal 2026?
Precision Biosciences (DTIL) reported revenue of $18K for the first quarter fiscal 2026 (Q1 FY26), -100% from a year earlier and -38% from the quarter before.